Lung Neoplasms Clinical Trial
Official title:
The Impact of Physical Activity on the Postoperative Symptoms, Complications, and Quality of Life Among Lung Cancer Survivors: A Prospective Cohort Study
Verified date | May 2024 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to examine the impact of physical activity on the postoperative symptoms, complication, and quality of life.
Status | Active, not recruiting |
Enrollment | 1050 |
Est. completion date | March 3, 2026 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who are diagnosed with lung cancer - Patients who are able to walk with ECOG (Eastern Cooperative Oncology Group) performance status < 1 - Patients who understand the purpose of this study and provide the written informed consent Exclusion Criteria: - Patients who have difficulty for walking - Patients with history of other cancer in the last 3 years - Patients with neoadjuvant chemotherapy and/or radiation therapy - Patients who are diagnosed with recurrent lung cancer or multiple cancer - Foreigner of patients from overseas who are not able regularly participate in this study |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change of quality of life: (EORTC QLQ) core30 (C30) | The change of quality of life is measured using the European Organization for Research Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) core30 (C30). The scale for quality of life is transformed into a score from 0 to 100, derived by 4-point Likert scale. A higher score represents a higher level of quality of life. | Before surgery (baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery | |
Secondary | Postoperative pulmonary complications | Incidence of pulmonary complications including air leak, atelectasis, pleural effusion, pneumonia, etc. | Within 30 days after surgery | |
Secondary | The change of symptom | The change of symptom is measured using the European Organization for Research Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) lung cancer module 13 (LC13). The scale for symptom is transformed into a score from 0 to 100, derived by 4-point Likert scale. A higher score represents a higher level of symptom. | Before surgery (baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|